Develops therapies for inflammatory and fibrotic diseases through targeting the endocannabinoid system.
Corbus Pharmaceuticals Holdings, Inc. is a biopharmaceutical firm dedicated to advancing therapies that modulate the immune system, with a focus on immuno-oncology and fibrosis diseases. At the forefront of its research is lenabasum, an oral compound designed to selectively activate cannabinoid receptor type 2 (CB2). Currently in Phase II clinical trials for systemic lupus erythematosus, lenabasum represents a promising avenue for treating autoimmune conditions. Additionally, Corbus Pharmaceuticals is pioneering CRB-601, an anti-integrin monoclonal antibody (mAb) targeting cancer and fibrosis by inhibiting the activation of transforming growth factor ß (TGFß), along with CRB-602, an anti-avß6/avß8 mAb aimed at fibrotic diseases by blocking TGFß activation.
In its robust pipeline, the comppany is also developing a cannabinoid receptor type 1 inverse agonist program, addressing metabolic disorders such as obesity, diabetic nephropathy, and nonalcoholic steatohepatitis, as well as various fibrotic diseases including lung, cardiac, renal disease, and liver fibrosis. Beyond these therapeutic areas, Corbus Pharmaceuticals explores treatments for conditions like ascites, cognitive defects, Prader-Willi syndrome, and smoking cessation. With a licensing agreement encompassing the Jenrin library of over 600 compounds, coupled with extensive patent filings, the company leverages its strategic partnerships to bolster its research and commercialization efforts.
Founded in 2009 and headquartered in Norwood, Massachusetts, Corbus Pharmaceuticals is committed to pushing the boundaries of biopharmaceutical innovation. Its comprehensive approach to developing novel therapies underscores its mission to improve the lives of patients worldwide, particularly those grappling with complex and debilitating diseases where current treatment options are limited.